✦ LIBER ✦

140 A prospective trial on the efficacy and tolerability of twice-daily dosing (TDD) versus once-daily dosing (ODD) amikacin in cystic fibrosis patients

✍ Scribed by S.S. Postnikov; S.Y. Semykin; S.V. Polikarpova; L.G. Dubovik; L.A. Gracheva; R.M. Sagatelyan

Book ID: 118641191
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 57 KB
Volume: 6
Category: Article
ISSN: 1569-1993
DOI: 10.1016/s1569-1993(07)60126-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A prospective, controlled, randomized, n

A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients

✍ Simeon Metallidis; Panagiotis Kollaras; Theodoros Giannakakis; Basilis Seitanidi 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 149 KB

Improved tolerability and quality of lif

Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-α-2b : Results of a randomized phase II trial of low-dose versus intermediate-dose interferon-α-2b in patients with metastatic renal cell carcinoma

✍ Nizar M. Tannir; Lorenzo Cohen; Xuemei Wang; Peter Thall; Paul F. Mathew; Eric J 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB 👁 2 views

80* A randomised, double-blind, placebo-

80* A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 μg and 5 μg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis

✍ J.S. Elborn; A. Sharma; Q. Deng; P. Koker 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 51 KB